GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

The following table provides a rollforward of the changes in the carrying amount of the Company’s goodwill:


	RMS		DSA(1)		Manufacturing		Total
	(in thousands)
December 26, 2020	$	287,759	$	1,378,130	$	143,279	$	1,809,168
Acquisitions	—		123,091		851,828		974,919
Divestitures	(4,129)		—		(27,764)		(31,893)
Foreign exchange	(106)		(28,715)		(11,492)		(40,313)
December 25, 2021	283,524		1,472,506		955,851		2,711,881
Acquisitions	215,752		—		(592)		215,160
Divestitures	—		—		(3,168)		(3,168)
Foreign exchange	(1,566)		(38,905)		(33,499)		(73,970)
December 31, 2022	$	497,710	$	1,433,601	$	918,592	$	2,849,903
(1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010.

Based on the Company’s quantitative goodwill impairment test, which was performed in the fourth quarter for each of the fiscal years 2022, 2021 and 2020, the fair value of each reporting unit exceeded the reporting unit’s book value and, therefore, goodwill was not impaired.

The increase in goodwill during fiscal year 2022 related primarily to the acquisition of Explora BioLabs in the RMS reportable segment, partially offset by a decrease due to the Avian divestiture impacting the Manufacturing reportable segment. The increase in goodwill during fiscal year 2021 related primarily to the acquisitions of Cognate and Vigene in the Manufacturing reportable segment and Distributed Bio and Retrogenix in the DSA reportable segment, partially offset by the decreases in the RMS and Manufacturing reportable segments due to the divestitures of RMS Japan and CDMO Sweden, respectively.

Intangible Assets, Net

The following table displays intangible assets, net by major class:


	December 31, 2022						December 25, 2021
	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
	(in thousands)
Backlog	$	15,236	$	(12,512)	$	2,724	$	12,577	$	(9,517)	$	3,060
Technology	129,626		(101,655)		27,971		135,764		(95,454)		40,310
Trademarks and trade names	12,617		(4,410)		8,207		13,086		(3,448)		9,638
Other	37,985		(22,122)		15,864		35,231		(8,445)		26,786
Client relationships	1,491,926		(591,417)		900,509		1,475,757		(494,359)		981,398
Intangible assets	$	1,687,390	$	(732,116)	$	955,275	$	1,672,415	$	(611,223)	$	1,061,192

The decrease in intangible assets, net during fiscal year 2022 related primarily to normal amortization over the useful lives and the Avian divestiture, partially offset by the acquisition of Explora BioLabs.

Amortization expense of definite-lived intangible assets, including client relationships, for fiscal years 2022, 2021 and 2020 was $146.6 million, $124.9 million and $111.9 million, respectively. As of December 31, 2022, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows:


Fiscal Year	Amortization Expense
	(in thousands)
2023	$	134,311
2024	$	122,612
2025	$	115,856
2026	$	108,436
2027	$	97,700